نتایج جستجو برای: oral etoposide

تعداد نتایج: 265365  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1999
K Hande M Messenger J Wagner M Krozely S Kaul

The objective of this study was to accurately determine the within- and between-patient variability in etoposide pharmacokinetics for i.v. and p.o. administered drug. Inter-and intrapatient variability in systemic etoposide exposure was measured following i.v. and p.o. drug administration using stable isotope dilution methodology. Seven patients received 50 mg of etoposide by both p.o. and i.v....

Journal: :Haematologica 1997
P Biglino P Perutelli P G Mori

Despite the heterogeneity and low number of patients treated, some preliminary observations can be made. The 25% overall response rate achieved is encouraging and compares favorably with other single-agent approaches, as well as with intravenous etoposide. Previous studies have also reported encouraging results using oral etoposide in untreated elderly AML patients. By contrast, the results rep...

Journal: :Archives of dermatology 1998
P Helmbold B Hegemann H J Holzhausen T Klapperstück W C Marsch

BACKGROUND The purpose of this study was to test the disease-controlling effect of low-dose oral etoposide monotherapy in adult-onset multisystem Langerhans cell histiocytosis. There are no previous reports of low-dose etoposide monotherapy for this condition. OBSERVATIONS A 27-year-old man with a 7-year history of multifocal chronic Langerhans cell histiocytosis presented with severe disabli...

Journal: :Experimental and Therapeutic Medicine 2010

Journal: :Tumori 2013
Rimas V Lukas Janani Vigneswaran Ravi Salgia

INTRODUCTION Progression of central nervous system (CNS) metastases from small cell lung cancer (SCLC) after radiation therapy is associated with a poor prognosis. CASE REPORTS We present two cases of patients with progressive CNS metastases from SCLC treated with oral temozolomide and etoposide. Sustained clinical responses and radiographic stability were demonstrated. The palliative chemoth...

Journal: :European journal of cancer 1997
T Sahmoud P E Postmus C van Pottelsberghe K Mattson L Tammilehto T A Splinter A S Planting T Sutedja J van Pawel N van Zandwijk P Baas K J Roozendaal M Schrijver A Kirkpatrick M Van Glabbeke A Ardizzoni G Giaccone

Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma. In the first trial, etoposide was given intravenously (i.v.) at a dose of 150 mg/m2 on days 1, 3 and 5 every 3 weeks. The second trial investigated a daily oral dose of 100 mg for 21 days followed by a 2-week treatment-free period, and then...

Journal: :Asian Pacific journal of cancer prevention : APJCP 2014
Seyda Gunduz Hasan Mutlu Sema Sezgin Goksu Deniz Arslan Ali Murat Tatli Mukremin Uysal Hasan Senol Coskun Hakan Bozcuk Mustafa Ozdogan Burhan Savas

BACKGROUND Malignant mesothelioma (MM) is almost always fatal and few treatment options are available. The aim of this study was to evaluate the efficacy of oral cyclophosphamide and etoposide for patients who underwent standard treatment for advanced MM. MATERIALS AND METHODS This study included 22 malignant pleural mesothelioma patients who were treated with oral cyclophosphamide and etopos...

Journal: :Cancer 2001
H G Munshi K J Pienta D C Smith

BACKGROUND A Phase II study was initiated to evaluate the effectiveness of an oral regimen of etoposide and estramustine in patients with early recurrent prostate carcinoma. METHODS Patients with early recurrent prostate carcinoma as indicated by an increasing prostate specific antigen (PSA) level and without any evidence of metastatic disease were treated with oral etoposide 50 mg/m2/day and...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید